Guangdong Taienkang Pharmaceutical 将来の成長

Future 基準チェック /56

Guangdong Taienkang Pharmaceutical利益と収益がそれぞれ年間37.7%と24.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に18.2% 37.4%なると予測されています。

主要情報

37.7%

収益成長率

37.4%

EPS成長率

Pharmaceuticals 収益成長	19.3%
収益成長率	24.5%
将来の株主資本利益率	18.2%
アナリストカバレッジ	Low
最終更新日	16 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Has A Meaningful Debt Burden

Nov 20

Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Sep 03

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Aug 23

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Jul 22

Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

May 22

Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

Feb 26

業績と収益の成長予測

SZSE:301263 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,362	378	N/A	336	2
12/31/2025	1,121	296	N/A	268	2
12/31/2024	914	223	N/A	167	2
9/30/2024	752	135	-149	28	N/A
6/30/2024	751	137	-153	48	N/A
3/31/2024	756	154	-191	17	N/A
12/31/2023	761	160	-106	94	N/A
9/30/2023	791	189	7	102	N/A
6/30/2023	814	206	46	155	N/A
3/31/2023	794	173	45	148	N/A
1/1/2023	783	175	59	149	N/A
9/30/2022	759	168	76	160	N/A
6/30/2022	712	140	49	112	N/A
3/31/2022	697	157	93	142	N/A
1/1/2022	654	120	75	120	N/A
9/30/2021	661	124	46	113	N/A
6/30/2021	668	127	53	123	N/A
3/31/2021	670	133	38	121	N/A
12/31/2020	709	161	32	126	N/A
9/30/2020	662	138	56	116	N/A
6/30/2020	612	119	79	120	N/A
3/31/2020	565	87	95	118	N/A
12/31/2019	496	55	67	75	N/A
9/30/2019	496	56	42	56	N/A
6/30/2019	512	69	40	62	N/A
3/31/2019	523	76	44	73	N/A
12/31/2018	514	74	39	69	N/A
9/30/2018	486	71	13	51	N/A
6/30/2018	480	67	N/A	44	N/A
3/31/2018	457	58	N/A	27	N/A
12/31/2017	450	55	N/A	23	N/A
9/30/2017	430	43	N/A	27	N/A
6/30/2017	408	35	N/A	21	N/A
3/31/2017	378	31	N/A	-10	N/A
12/31/2016	367	28	N/A	2	N/A
9/30/2016	382	38	N/A	10	N/A
6/30/2016	398	49	N/A	19	N/A
3/31/2016	384	45	N/A	17	N/A
12/31/2015	370	42	N/A	16	N/A
9/30/2015	337	36	N/A	N/A	N/A
6/30/2015	304	29	N/A	7	N/A
3/31/2015	305	35	N/A	28	N/A
12/31/2014	304	40	N/A	25	N/A
12/31/2013	280	48	N/A	19	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 301263の予測収益成長率 (年間37.7% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 301263の収益 ( 37.7% ) はCN市場 ( 26% ) よりも速いペースで成長すると予測されています。

高成長収益: 301263の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 301263の収益 ( 24.5% ) CN市場 ( 13.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: 301263の収益 ( 24.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 301263の自己資本利益率は、3年後には低くなると予測されています ( 18.2 %)。

Guangdong Taienkang Pharmaceutical 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Has A Meaningful Debt Burden

Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.073 in 3Q 2023)

Guangdong Taienkang Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 23%

Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)

Second quarter 2024 earnings released: EPS: CN¥0.091 (vs CN¥0.14 in 2Q 2023)

Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable

Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly

Guangdong Taienkang Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year

Dividend of CN¥0.30 announced

First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 1Q 2023)

Guangdong Taienkang Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Now 20% undervalued after recent price drop

Guangdong Taienkang Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorates as stock falls 16%

Guangdong Taienkang Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024

Third quarter 2023 earnings released: EPS: CN¥0.073 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.055 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Guangdong Taienkang Pharmaceutical Co., Ltd Approves Cash Dividend for 2022

Investor sentiment improves as stock rises 16%

First quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.30 in 1Q 2022)

Guangdong Taienkang Pharmaceutical Co., Ltd (SZSE:301263) entered into an investment agreement to acquire BCY Pharm Co., Ltd from Nanjing Baijiahui Biotechnology Development Co., Ltd for CNY 200 million.

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.13 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.099 (vs CN¥0.22 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Guangdong Taienkang Pharmaceutical Announces A 2021 Final Profit Distribution Payable on 30 May 2022

Guangdong Taienkang Pharmaceutical Announces A 2021 Final Profit Distribution Payable on 30 May 2022

Guangdong Taienkang Pharmaceutical Co., Ltd Approves Cash Dividend for 2021

Guangdong Taienkang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.16 in 1Q 2021)

Investor sentiment deteriorated over the past week

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘